Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,185
  • Shares Outstanding, K 44,677
  • Annual Sales, $ 360 K
  • Annual Income, $ -28,290 K
  • 60-Month Beta 1.67
  • Price/Sales 190.77
  • Price/Cash Flow N/A
  • Price/Book 0.67
Trade CRDF with:

Options Overview Details

View History
  • Implied Volatility 146.03% ( -28.58%)
  • Historical Volatility 83.69%
  • IV Percentile 44%
  • IV Rank 17.19%
  • IV High 595.20% on 12/09/22
  • IV Low 52.76% on 02/08/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 167
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 6,233
  • Open Int (30-Day) 5,121

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.25
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.30
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4400 +34.03%
on 01/10/23
2.0400 -5.39%
on 02/03/23
+0.4500 (+30.41%)
since 01/03/23
3-Month
1.2000 +60.83%
on 12/20/22
2.0400 -5.39%
on 02/03/23
+0.5100 (+35.92%)
since 11/03/22
52-Week
1.1300 +70.80%
on 05/11/22
3.5600 -45.79%
on 02/07/22
-1.2200 (-38.73%)
since 02/03/22

Most Recent Stories

More News
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials

EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END

TCBP : 5.68 (+5.19%)
TCBPW : 0.1210 (-3.20%)
CRDF : 1.9300 (+10.29%)
CYAD : 1.2400 (-1.59%)
RIGL : 1.7900 (+1.13%)
AZN : 63.44 (+0.46%)
Cardiff Oncology to Present at Upcoming Investor Conferences

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

CRDF : 1.9300 (+10.29%)
Cardiff Oncology to Present at the Jefferies London Healthcare Conference

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

CRDF : 1.9300 (+10.29%)
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies

Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound,...

ONCY : 1.8100 (-1.63%)
ONC.TO : 2.48 (unch)
CLVS : 0.0812 (-5.58%)
OPK : 1.3900 (-3.47%)
CRDF : 1.9300 (+10.29%)
MRK : 102.94 (-0.50%)
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 25.93% and 24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CRDF : 1.9300 (+10.29%)
VCEL : 31.06 (-0.89%)
Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

CRDF : 1.9300 (+10.29%)
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028

Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...

KTTA : 0.6780 (-6.61%)
AZN : 63.44 (+0.46%)
LOGC : 2.07 (+0.49%)
CRDF : 1.9300 (+10.29%)
SWTX : 31.69 (-6.93%)
DAWN : 21.11 (-2.94%)
Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates

Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib's contribution to SoC and position for a possible...

CRDF : 1.9300 (+10.29%)
Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022

Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus...

CRDF : 1.9300 (+10.29%)
Cardiff Oncology to Present at Upcoming Investor Conferences in September

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

CRDF : 1.9300 (+10.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

3rd Resistance Point 2.3933
2nd Resistance Point 2.2167
1st Resistance Point 2.0733
Last Price 1.9300
1st Support Level 1.7533
2nd Support Level 1.5767
3rd Support Level 1.4333

See More

52-Week High 3.5600
Fibonacci 61.8% 2.6317
Fibonacci 50% 2.3450
Fibonacci 38.2% 2.0583
Last Price 1.9300
52-Week Low 1.1300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar